Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying antirheumatic drugs

E Li1, P Brooks, P G Conaghan

  • 1University of New South Wales, School of Medicine, St. Vincent's Hospital, Darlinghurst, Australia.

Current Opinion in Rheumatology
|June 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of different vitamin D supplements on body fat distribution and glucolipid metabolism in patients with obesity-associated metabolic syndrome: A meta-analysis.

Medicine·2026
Same author

Author Correction: Projectome-based characterization of hypothalamic peptidergic neurons in male mice.

Nature neuroscience·2025
Same author

Improvement in the quality of the water-saving and drought-resistant rice 'Huhan 1516' via molecular markers.

Molecular breeding : new strategies in plant improvement·2025
Same author

<sup>177</sup>Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Effects of apigenin on the proliferation, migration, and apoptosis of human diffuse large B-cell lymphoma OCI-LY3 cells.

Discover oncology·2025
Same author

Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction.

Cell insight·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Disease-modifying antirheumatic drugs (DMARDs) are the primary treatment for rheumatoid arthritis, with combination therapy showing promise. Careful patient selection and monitoring are crucial for managing adverse reactions and improving treatment efficacy.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Disease-modifying antirheumatic drug (DMARD) therapy is the cornerstone of rheumatoid arthritis (RA) treatment.
  • There is a growing emphasis on combination DMARD therapy for RA management.

Purpose of the Study:

  • To review the current understanding of DMARDs in RA treatment.
  • To highlight challenges and findings related to DMARD combination therapy.
  • To discuss adverse reactions and monitoring strategies for DMARDs.

Main Methods:

  • Review of existing data on DMARD combination therapy in RA.
  • Analysis of challenges in conducting combination therapy studies.
  • Evaluation of adverse event frequencies and risk factors.

Main Results:

Related Experiment Videos

  • Combination therapy studies for RA are complex and require large patient cohorts.
  • Early RA patient populations are emphasized in combination studies.
  • Despite aggressive DMARD use, most patients develop erosions.
  • Reappraisal of monitoring strategies is needed due to low adverse event frequencies (e.g., ophthalmologist reviews for antimalarials).
  • Risk factors for methotrexate-associated pulmonary toxicity have been identified.

Conclusions:

  • DMARDs are unequivocally effective in treating RA.
  • Further research is needed to determine optimal DMARD combinations for improved efficacy.
  • Ongoing evaluation of DMARD effectiveness and safety is essential for RA patient care.